Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis
- 328 Downloads
Infantile neuronal ceroid lipofuscinosis (INCL) is a profoundly neurodegenerative disease of children caused by a deficiency in the lysosomal enzyme palmitoyl protein thioesterase-1 (PPT1). There is currently no effective therapy for this invariably fatal disease. To date, preclinical experiments using single treatments have resulted in incremental clinical improvements. Therefore, we determined the efficacy of CNS-directed AAV2/5-mediated gene therapy alone and in combination with the systemic delivery of the lysosomotropic PPT1 mimetic phosphocysteamine. Since CNS-directed gene therapy provides relatively high levels of PPT1 activity to specific regions of the brain, we hypothesized that phosphocysteamine would complement that activity in regions expressing subtherapeutic levels of the enzyme. Results indicate that CNS-directed gene therapy alone provided the greatest improvements in biochemical and histological measures as well as motor function and life span. Phosphocysteamine alone resulted in only minor improvements in motor function and no increase in lifespan. Interestingly, phosphocysteamine did not increase the biochemical and histological response when combined with AAV2/5-mediated gene therapy, but it did result in an additional improvement in motor function. These data suggest that a CNS-directed gene therapy approach provides significant clinical benefit, and the addition of the small molecule PPT1 mimetic can further increase that response.
KeywordsResveratrol Brain Weight Lysosomal Storage Disease CD68 Immunoreactivity Infantile Neuronal Ceroid Lipofuscinosis
We would like to thank Beth Eultgen for her help with animal husbandry. This study was supported by NIH grants (NS043105; MSS), Ruth L. Kirschstein NRSA Fellowship (NS056728; SLM), The Wellcome Trust (GR079491MA; JDC, AMW, DY), Batten Disease Family Association (JDC, AMW, DY), the Batten Disease Support and Research Association (JDC, AMW, DY, SLM, MSS), and the Bletsoe Family (JDC, AMW).
- Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302–317Google Scholar
- Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen, Zabner J, Ghodsi A, Chiorini JA (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci 97:3428–3432Google Scholar
- Griffey M, Bible E, Vogler C, Levy B, Gupta P, Cooper J, Sands MS (2004) Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 16:360–369PubMedCrossRefGoogle Scholar
- Hofmann SL, Peltonen L (2001) The neuronal ceroid lipofuscinosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease. New York, McGraw-Hill, pp 3877–3894Google Scholar
- Sands MS, Barker J, Vogler C, Levy B, Gwynn B, Galvin N, Birkenmeier EH (1993) Treatment of murine mucopolysaccharidosis type VII in newborns by syngeneic bone marrow transplantation. Lab. Invest. 68:676–686Google Scholar